Bloomberg Law
Sept. 17, 2021, 8:32 PM

Exelixis Gets FDA Approval of Cabometyx For Thyroid Cancer

Cara Moffat
Cara Moffat
Bloomberg News

Exelixis has received U.S. FDA approval of Cabometyx in patients 12 years and older with previously treated radioactive iodine-refractory differentiated thyroid cancer.

  • Approval ahead of PDUFA target date of Dec. 4, 2021
  • Approval based on results from COSMIC-311 trial
  • Co. says it’s prepared to fully support expanded indication immediately
  • Exelixis shares up over 2% in extended trading

To view the source of this information, click here

To contact the reporter on this story:
Cara Moffat in Los Angeles at

To contact the editor responsible for this story:
Lauren Berry at

© 2021 Bloomberg L.P. All rights reserved. Used ...